- $23.62m
- $29.86m
- $0.34m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 67.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -193.48% | ||
| Return on Equity | n/a | ||
| Operating Margin | -8043.14% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.21 | 0.72 | 0.47 | 0.65 | 0.34 | 0.25 | 4.37 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Directors
- Shalom Jacobovitz NEC (60)
- Robert Etherington PRE (54)
- Mark Mortenson CFD (64)
- Morgan Brown CFO
- Robert Glanzman OTH (64)
- Reed Wilcox DRC (72)
- Fiona Costello IND (51)
- Jonathan Gay IND (43)
- David Matlin IND (59)
- Vallerie Mclaughlin IND
- Alison Mosca IND (47)
- John Stevens IND (60)
- Chidozie Ugwumba IND (38)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- August 12th, 2020
- Public Since
- August 27th, 2018
- No. of Shareholders
- 68
- No. of Employees
- 75
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 8,982,747
- Address
- 6550 South Millrock Drive, Suite G50, SALT LAKE CITY, 84121
- Web
- https://clene.com/
- Phone
- +1 8016769695
- Auditors
- Deloitte & Touche LLP
Upcoming Events for CLNN
Clene Inc. Annual Shareholders Meeting
Q2 2025 Clene Inc. Earnings Release
Q3 2025 Clene Inc. Earnings Release
Similar to CLNN
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Clene. share price?
As of Today at 19:58 UTC, shares in Clene. are trading at $2.63. This share price information is delayed by 15 minutes.
How has the Clene. share price performed this year?
Shares in Clene. last closed at $2.63 and the price had moved by -66.02% over the past 365 days. In terms of relative price strength the Clene. share price has underperformed the S&P500 Index by -68.65% over the past year.
What are the analyst and broker recommendations for Clene.?
The overall consensus recommendation for Clene. is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Clene. dividend yield?
Clene. does not currently pay a dividend.
Does Clene. pay a dividend?
Clene. does not currently pay a dividend.
When does Clene. next pay dividends?
Clene. does not currently pay a dividend.
How do I buy Clene. shares?
To buy shares in Clene. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Clene.?
As of the previous close price of $2.63, shares in Clene. had a market capitalisation of $23.62m.
Where are Clene. shares listed?
Here are the trading details for Clene.:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CLNN
What kind of share is Clene.?
Based on an overall assessment of its quality, value and momentum Clene. is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Clene. share price forecast for 2025?
The analyst consensus target price for shares in Clene. is $43.00. That is 1534.98% above the last closing price of $2.63.
Analysts covering Clene. currently have a consensus Earnings Per Share (EPS) forecast of -$3.16 for the next financial year.
Find out moreWhat is the trend in the Clene. share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clene.. Over the past six months, its share price has underperformed the S&P500 Index by -50.99%.
As of the last closing price of $2.63, shares in Clene. were trading -43.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Clene. PE Ratio?
The Clene. PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.63.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Clene.?
Clene.'s management team is headed by:
- Shalom Jacobovitz - NEC
- Robert Etherington - PRE
- Mark Mortenson - CFD
- Morgan Brown - CFO
- Robert Glanzman - OTH
- Reed Wilcox - DRC
- Fiona Costello - IND
- Jonathan Gay - IND
- David Matlin - IND
- Vallerie Mclaughlin - IND
- Alison Mosca - IND
- John Stevens - IND
- Chidozie Ugwumba - IND